Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung

Lung Cancer

Volumn 40, Issue 2, 2003, Pages 173-180

  Araki, Kazuhiro ^a,b   Ishii, Genichiro ^a   Yokose, Tomoyuki ^a   Nagai, Kanji ^b   Funai, Kazuhito ^a,b   Kodama, Keiji ^a   Nishiwaki, Yutaka ^b   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

c Kit; Immunohistochemistry; Large cell neuroendocrine carcinoma; Overexpression; Small cell lung carcinoma; Tyrosine kinase receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; BRONCHUS CARCINOID; CANCER SURGERY; CANCER TISSUE; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0037404766     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00034-5     Document Type: Article

References (39)

1. Travis WD, Colby TV, Corrin B, et al. International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours 1999.
2. Travis W.D., Rush W., Flieder D.B., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am. J. Surg. Pathol. 22:1998;934-944.
3. Colby TV, Koss MN,Travis WD. Atlas of Tumors Pathology. Tumors of the Lower Respiratory Tract. Tumors of the Lower Respiratory Tract 1995; 13.
4. Hunter T. Oncoprotein networks. Cell. 88:1997;333-346.
5. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:1995;179-185.
6. Menard S., Fortis S., Castiglioni F., Agresti R., Balsari A. HER2 as a prognostic factor in breast cancer. Oncology. 61:2001;67-72.
7. Lasota J., Jasinski M., Sarlomo-Rikala M., Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 154:1999;53-60.
8. Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 59:1999;4297-4300.
9. Kim Y.T., Park S.W., Kim J.W. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol. Oncol. 87:2002;84-89.
10. Fernandes A.M., Hamburger A.W., Gerwin B.I. Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity. Am. J. Respir. Cell. Mol. Biol. 21:1999;701-709.
11. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer.Res. 6:2000;4885-4892.
12. Raben D., Helfrich B.A., Chan D., Johnson G., Bunn P.A. Jr. ZD 1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin. Oncol. 29:2002;37-46.
13. Bunn P.A. Jr, Helfrich B., Soriano A.F., et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res. 7:2001;3239-3250.
14. Arber D.A., Tamayo R., Weiss L.M. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum. Pathol. 29:1998;498-504.
15. Strohmeyer T., Peter S., Hartmann M., et al. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res. 51:1991;1811-1816.
16. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
17. Sekido Y., Obata Y., Ueda R., et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 51:1991;2416-2419.
18. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
19. Sawyers C.L., Druker B. Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. Sci. Am. 5:1999;63-69.
20. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 358:2001;1421-1423.
21. Wang W.L., Healy M.E., Sattler M., et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19:2000;3521-3528.
22. International Union Against Cancer (UICC): Lung. Sobin L.H., Wittekind C.B. TNM classification of malignant tumors. fifth ed:1997;Wiley-Liss, New York.
23. Berman J., O'Leary T.J. Gastrointestinal stromal tumor workshop. Hum. Pathol. 32:2001;578-582.
24. Tazawa K., Tsukada K., Makuuchi H., Tsutsumi Y. An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol. Int. 49:1999;786-798.
25. Hirashima N., Takahashi W., Yoshii S., Yamane T., Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod. Pathol. 14:2001;556-562.
26. Pfeiffer P., Nexo E., Bentzen S.M., et al. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br. J. Cancer. 78:1998;96-99.
27. Yokose T., Suzuki K., Nagai K., et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 29:2000;179-188.
28. Hibi K., Takahashi T., Sekido Y., et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 6:1991;2291-2296.
29. Plummer H. III, Catlett J., Leftwich J., et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53:1993;4337-4342.
30. Rygaard K., Nakamura T., Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. Br. J. Cancer. 67:1993;37-46.
31. Witte O.N. Steel locus defines new multipotent growth factor. Cell. 63:1990;5-6.
32. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6:2000;3319-3326.
33. Ernst S.I., Hubbs A.E., Przygodzki R.M., et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab. Invest. 78:1998;1633-1636.
34. Moskaluk C.A., Tian Q., Marshall C.R., et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene. 18:1999;1897-1902.
35. Sakurai S., Fukasawa T., Chong J.M., Tanaka A., Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumors of interstitial cells of Cajal. Jpn. J. Cancer Res. 90:1999;1321-1328.
36. Jeng Y.M., Lin C.Y., Hsu H.C. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 154:2000;107-111.
37. Takei H., Asamura H., Maeshima A., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of 87 cases. J. Thorac. Cardiovasc. Surg. 124:2002;285-292.
38. Sekido Y., Takahashi T., Ueda R., et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res. 53:1993;1709-1714.
39. Johnson B.E., Fisher B., Fisher T., et al. Phase II study of STI571 (Gleeve) for patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 154:2002;293a.